Apyx Medical Corporation provided earnings guidance for the year ending December 31, 2024. For the year, the company expects Total revenue in the range of $49.7 million to $52.9 million, representing a decrease of approximately 5% to growth of approximately 1% year-over-year, compared to total revenue of $52.3 million for the year ended December 31, 2023. Net loss attributable to stockholders of approximately $26.5 million to $24.3 million, compared to $18.7 million for the year ended December 31, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.35 USD | -4.26% | -3.57% | -48.47% |
04-05 | Archon Capital Management Engages with Apyx Medical Corporation | CI |
04-01 | Stavros G. Vizirgianakis Engages in Discussions with Apyx Medical Corporation | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.47% | 48.85M | |
-4.66% | 185B | |
-1.01% | 109B | |
-4.20% | 68.54B | |
+2.68% | 51.74B | |
+9.12% | 45.22B | |
+3.83% | 41.74B | |
+4.13% | 26.83B | |
+3.31% | 26.69B | |
+13.67% | 25.63B |
- Stock Market
- Equities
- APYX Stock
- News Apyx Medical Corporation
- Apyx Medical Corporation Provides Earnings Guidance for the Year Ending December 31, 2024